A B S T R A C T The secretory pancreatic proteins in serum were analyzed in a group of cigarette smokers and a control group of nonsmokers before and after intravenous secretin stimulation. None of these persons had any signs of pancreatic disease. In the control group, serum total amylase activity, pancreatic isoamylase, cationic trypsinogen, and pancreatic secretory trypsin inhibitor concentrations varied within the normal range before and after secretin injection. In contrast, the concentrations of these pancreatic proteins in all the cigarette smokers elevated from normal to abnormally high serum concentrations after secretin stimulation. The results indicate a probable toxic effect of cigarette smoking on the exocrine pancreas.
INTRODUCTION
Inflammatory and neoplastic diseases of the exocrine pancreas are increasing. In the United States (1), pancreatic carcinoma is the fourth leading cause of cancerrelated mortality, and at autopsy 2% of deaths are related to the pancreas (2) . Many environmental and chemical agents have been related to pancreatic diseases (3, 4, 5) . Tobacco smoke contains multiple agents with cytotoxic or carcinogenic effects on the exocrine pancreas (2, 3) , and studies have shown a close correlation between cigarette smoking and pancreatic cancer (4, 6) .
There is a need for rapidly improved diagnostic laboratory methods in treating pancreatic disease. This has led to increased interest in the endogenous turnover of secretory pancreatic proteins. Serum amylase and its isozymic forms are well known (7, 8) , using radioimmunoassay, other pancreatic proteins have been determined in serum, e.g., cationic trypsinogen (9) and pancreatic secretory trypsin inhibitor (10) .
Incidently, a rise above normal of some of the secretory pancreatic proteins was noted in a few members of a "normal" group undergoing secretin stimulation tests. These people were cigarette smokers.
The purpose of our study was to compare the effects of secretin stimulation on the serum level of amylase, cationic trypsinogen, and pancreatic secretory trypsin inhibitor in nonsmokers and long-term cigarette smokers.
METHODS
24 subjects, randomly selected from among students, hospital professional staff, and patients without signs of abdominal disease, including both sexes, aged 25-70, took part in this study. All had smoked cigarettes for 5-40 yr, and at the time of this study smoked 10-40 cigarettes daily. 12 healthy volunteer students and hospital professional staff, aged 25-70, served as a control group. Eight had never smoked cigarettes and four had stopped smoking at least 3 yr before this study.
Both the conitrol and smoking groups had an equal number of social drinkers with an average monthly intake of <100 g of alcohol. No subject used had a history of alcohol abuse.
Secretin was a product of AB Kabi Diagnostica, Stockholm, Sweden. 75 clinical units in 10 ml of 0.9% NaCl was injected intravenously over 2 min. Sephadex G-100 was obtained from Pharmacia Fine Chemicals Inc., Uppsala, Sweden.
Monospecific rabbit antisera against human a1-antitrypsin and a2-macroglobulin are regularly produced in our own laboratory. The secretin stimulation test was performed in the morning before breakfast and after a 12-h overnight fast. Cigarette smoking was denied from the start of the fast until completion of the test. Blood samples were drawn from a peripheral vein and collected in test tubes 10 min before, and 15 and 30 min after the injection of secretin. After coagulation and centrifugation, about 4 ml of serum was collected from each tube and immediately frozen. The subjects suffered no ill effects.
Total serum amylase activity was performed with the Phadebas Amylase test (Pharmacia Diagnostica AB, Uppsala, Sweden). Normal equals 1.2-5.0 gecat/liter.' Serum pancreatic isoamylase activity was determined according to Skude (8) . Normal equals 0.75-2.9 ,ucat/liter. Immunoreactive cationic trypsinogen in serum was determined by radioimmunoassay according to Borgstrom (9) . Normal equals 15-50 ,ug/liter. Immunoreactive pancreatic secretory trypsin inhibitor was determined by radioimmunoassay according to Eddeland et al. (10) .
Normal equals 6-18 pg/liter. Gel filtration of serum samples was done on a Sephadex G-100 column (1.5 x 35 cm, 2.4 ml/h). Each sample (0.5 ml) was applied and eluted with 0.01 M tris-HCl buffer, pH 7.4, containing NaCl (0.12 mol/ liter) and EDTA (0.005 mol/liter). Fractions of 0.9 ml were collected. a,-Antitrypsin and a2-macroglobulin concentrations were determined by electroimmunoassay (11) .
Statistical methods. Comparisons between serum values before and after secretin stimulation were carried out by t test for paired and unpaired observations (P < 0.01 = significant; P < 0.001 = highly significant).
RESULTS
In the control group the serum values of total amylase activity, pancreatic isoamylase, cationic trypsinogen, and pancreatic secretory trypsin inhibitor were within normal limits before, and 15 and 30 min after secretin injection (Table I, Fig. 1 ). All subjects in the smoking group, however, showed a uniform increase above the normal range for all parameters determined following secretin stimulation.
Total amylase activity. Before secretin injection, the mean total serum amylase activity in the smoking group was 4.1 ,ucat/liter as compared with 3 concentrations were 6.0 and 6.9 ,ucat/liter, respectively, in the smoking group (Table I) . Immunoreactive cationic trypsinogen. The mean concentration of cationic trypsinogen in the test serum was 37 ,ugliter before the secretin injection with a corresponding value in the control group of 24 ,ug/liter (P < 0.01). 15 and 30 min after the secretin stimulation, the mean values in serum were 176 and 174 ,ug/liter, respectively (P < 0.001) (Fig. 1) .
Immunoreactive pancreatic secretory trypsin inhibitor. Before injection, the mean value of pancreatic secretory trypsin inhibitor in the test serum was 13 ,ug/liter with a corresponding control value of 9.5 gg/l (P < 0.01). 15 and 30 min after secretin stimulation, the mean serum values were 22 and 20,g/liter, respectively. (P < 0.001) (Fig. 2) .
Gel filtration of serum samples obtained from persons in the smoking group before and after the secretin stimulation showed all immunoreactive cationic trypsinogen and pancreatic secretory trypsin inhibitor recovered in volumes corresponding to free cationic trypsinogen (-25,000 mol wt) and free pancreatic secretory trypsin inhibitor (-7,000 mol wt). cationic trypsinogen was eluted corresponding to a2-macroglobulin (-725,000 mol wt) or a,-antitrypsin (-55,000 mol wt) (Fig. 3) .
DISCUSSION
Serum levels of secretory pancreatic proteins become markedly elevated with obstruction of the pancreatic duct. The increased ductal pressure may lead to movement of zymogens into the periacinar space, where acinar cell damage may be induced upon activation of the zymogens (12) . Passage of pancreatic proteins into lymphatic and blood capillaries in the peripancreatic connective tissue can then lead to the elevated serum levels seen in acute pancreatitis (13) (14) (15) (16) insights may help explain the false positive results previously reported for individuals with apparently healthy glands. In nonsmoking healthy subjects, conventional intravenous doses of secretin caused no elevation of serum pancreatic secretory proteins. In cigarette smokers, however, secretin stimulation caused three-to fivefold increase of a series of secretory pancreatic proteins in serum within 15 min. None of these individuals had clinical signs or a history of pancreatic disease. Their initial serum concentrations of secretory pancreatic proteins were within the normal reference range, but slightly higher than in the control group. Thus, cigarette smokers seem to have a greater reflux of secretory pancreatic proteins into the blood. This reflux is dramatically increased with secretin stimulation. The exact mechanism behind this increased "leakiness" ofthe pancreatic gland in cigarette smokers remains to be elucidated. Several alternative explanations are possible, such as "subclinical" pancreatic cell injury caused by cytotoxic substances in the smoke or sustained increased intraductal pressure induced by the complex pharmacological actions of nicotine.
Gel filtration of the serum samples from smokers (Fig. 3) demonstrated that only trypsinogen, not trypsin, is found in the circulation after secretin stimulation. If active trypsin had been present, one would have expected to find it bound to its major serum protease inhibitors, a1-antitrypsin and a%-macroglobulin (23) . This finding also contradicts a possible absorption of pancreatic enzymes from the intestine in smokers (24) .
Our study clearly pinpoints an unexpected effect of cigarette smoking on the exocrine pancreas, and further analyses are underway in our laboratory to determine the significance ofthis finding. The methods used in this study may form the basis for simple tests to unmask functional disorders ofthe exocrine pancreas caused by exposure to cytotoxic or carcinogenic agents.
